Nvidia and Pfizer have led an $80 million funding round for Israeli medical AI startup CytoReason. The funding also saw participation from Thermo Fisher and OurCrowd. CytoReason, which specializes in using AI to develop disease models, plans to open a new office in Massachusetts. The investment is seen as a significant boost for the medical tech industry, highlighting the growing interest in AI-driven healthcare solutions.